Stories

New in our A Life in Science series, we hear from Mary Jane Hinrichs, Senior Vice President and Head of Early Development, about her path from discovering a passion for pharmacology to leading drug candidates through first-in-human trials. She shares how balancing strategy, science, and a constant focus on patients motivates her to shape the future of medicines.

A replay with complete presentation and Q&A session will be made available soon after the Annual General Meeting.

New in our A Life in Science series, we hear from Elodie Lewkowicz, Asset Lead, about how curiosity and collaboration drive her mission to tackle the complexity of cancer. She reflects on mentoring, developing the next generation of scientists, and keeping patients at the heart of every data point to stay motivated through challenges.

The European Neuroendocrine Tumor Society (ENETS) 4 – 6 March 2026 conference in Kraków is one of the most important moments of the year for the global NET community. Clinicians, researchers, nurses, advocates and partners come together with a shared purpose to expand understanding of neuroendocrine tumors (NETs) and improve care for people living with them.

Every year, new breakthroughs reveal possibilities for treating conditions once thought untreatable. But possibility alone is not enough. The true challenge lies in identifying compelling scientific opportunities early—and shaping them deliberately so they can one day make a meaningful impact for patients. At Ipsen, we recognize the potential of early science; where bold ideas thrive and where there is the greatest risk but also the potential to change patients’ lives.